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PROTECTED BY ANTIRETROVIRAL 
DRUG STRATEGIES THAT PRESERVE 
BREASTFEEDING BY HIV-POSITIVE WOMEN
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Health, Columbia University, New York, USA
The Tshwane Declaration of Support for Breastfeeding in South 
Africa was recently championed by the national Department of 
Health as a concrete step to improving maternal and child health 
in the country. Saloojee, Gray and McIntyre (in the December 
2011 edition of this journal) state they are not opposed to this 
declaration, and welcome the greater support for application of 
baby-friendly principles in the health services, strengthening 
community-based programmes to support breastfeeding, and 
stricter legislation to protect the rights of breastfeeding mothers. 
They objected to only one item concerning the withdrawal of free 
formula for HIV-positive women, and lamented that there has 
been hardly any response from clinicians, health professionals or 
civil society groups to this decision. Aside from their objections, 
the overwhelming response to the Tshwane Declaration from 
clinicians, health professionals and civil society groups has been 
enthusiastic support. Moreover, the Tshwane Declaration itself was 
a culmination of more than two years of consultation between the 
Department of Health and clinicians, health professionals, civil 
society groups, including activists and women living with HIV, and 
Saloojee et al. themselves.
The latter authors state that the evidence base for withdrawal 
of formula is inadequate. In this paper, I present the extensive 
evidence base supporting the new South African government 
policies. The evidence is strong that provision of free infant formula 
is dangerous and that antiretroviral drugs (ARVs) work. I also 
discuss whether withdrawal of free formula could be considered 
unconstitutional – a very important accusation, and one which 
requires thoughtful consideration.
BREASTFEEDING SAVES LIVES
Saloojee et al. assert that to withdraw support for free formula is 
a luxury that South Africa can ill afford unless there is ‘substantial 
evidence that the strategy is either ineffective or results in major 
harm’ [emphasis added]. While these are reasonable criteria on 
which to make any decision about public health, it is extraordinary 
that they appear to disregard the overwhelming evidence from 
around the African continent, including countries in southern 
Africa, that formula feeding is associated with significantly higher 
mortality in young infants. It is precisely the accumulation of 
substantial evidence that provision of infant formula is either 
futile or results in major harm that informed the international 
recommendations released by the World Health Organization to 
guide national ministries of health.1
Human breast milk is exquisitely regulated, containing not only 
nutrients but also immunologically active components to protect 
newborns against disease and support the maturation of their own 
immune system.2 Medical research dating back to the Middle Ages 
identified that orphans and abandoned infants would die unless 
human breast milk were provided.3 An experiment was undertaken 
in the 1970s by formula manufacturers, confident in their ‘modern’ 
product, who began marketing it in African countries. Provision of 
infant formula correlated with infant deaths.4 Fortunately, these 
deaths also sparked effective pro-breastfeeding advocacy that 
has helped to shape global public health initiatives. There are 
extensive biological, clinical, epidemiological and programmatic 
data indicating that infant formula results in major harm to 
infants and their mothers. Consequently, it is a falsehood to say 
that evidence showing the major harm associated with provision 
of formula is ‘simply lacking’. There is overwhelming evidence of 
the harmful effects of formula feeding in the general population 
in southern Africa and elsewhere for decades. Until recently, there 
was indeed a lack of evidence of any comparable effect among 
HIV-infected mothers and their exposed but uninfected infants. 
Yet there is now substantial evidence in better- and less-resourced 
settings, including the better-resourced settings of South Africa 
and Botswana, that formula feeding results in elevated death 
rates among children who would otherwise be HIV-uninfected and 
alive. The serious threat to infant survival is the most important 
justification for the withdrawal of Department of Health support 
for infant formula.
The South African Department of Health is justified in withdrawing support for free infant formula. By so doing, it recognises that any 
intervention that might detract from breast feeding poses a serious threat to infant survival. Since evidence is now strong that antiret-
roviral drugs used during lactation prevent transmission of infection from a seropositive mother, strategies that promote breastfeed-
ing can now be recommended for enhancing the health of mothers and infants.
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IS HIV IN SOUTH AFRICA THE EXCEPTION?
Saloojee et al. do not appear to be aware of this expanse of 
biological, clinical, epidemiological and programatic research. 
It seems that their position can only be held if they subscribe to 
two types of ‘exceptionalism’: (i) HIV exceptionalism and (ii) South 
African exceptionalism.
Postnatal transmission of HIV through breastfeeding is indeed a 
special case that requires cautious and courageous consideration 
of appropriate infant feeding policy. HIV transmission can occur 
throughout the period of breastfeeding, therefore complete 
abstention from breastfeeding will obviously not permit any 
transmission to occur via this route. Abstention from breastfeeding 
will not, however, prevent intrauterine or intrapartum transmission. 
In the absence of interventions, most (~70%) infants born to 
and breastfed by HIV-positive mothers will remain uninfected. 
When HIV-positive women avoid breastfeeding with the goal of 
preventing the proportion of vertical transmission attributable 
to breastfeeding, they place their infants at risk of malnutrition, 
pneumonia and diarrhoeal morbidity and mortality as well as 
increasing the child’s risk of developmental and cognitive delays. 
This is the nub of the dilemma, and provision of free formula is not 
a solution; instead, it’s part of the dilemma that the HIV epidemic 
has made us face.
In the era prior to the demonstration that ARVs used during 
lactation can provide a constructive solution to the infant-feeding 
dilemma, two wish-fulfillment strategies were used instead: Either 
deny that HIV is transmitted through breastfeeding or deny that 
there are substantial risks of death and other serious outcomes 
from formula feeding. Study after study clearly showed that HIV 
is transmitted to infants through breastfeeding. Denial of the 
dangers of formula became the more popular position. In 2000, 
the WHO recommended that HIV-infected women provide formula 
feeds to their infants as a means of preventing HIV infection. This 
guidance was based on the premise and intention that public 
health programmes could be set up that would eliminate the risks 
associated with handing out formula feeds. This strategy was very 
powerful because it was able to mobilise resources to buy formula 
for programmes and for research. But the strategy set aside the 
large body of breastfeeding research that had been conducted 
among non-HIV-infected women that had described and quantified 
the excess risk of death associated with formula feeds; it called for 
new research and evidence to record the experiences and measure 
the effects of using formula feeds by HIV-infected mothers.
For better or worse, several groups, including my own, bought 
into this notion and conducted studies to test whether complete 
avoidance of breastfeeding, or shortening the duration of 
breastfeeding, would have adverse consequences for infants born 
to HIV-positive mothers. Sadly, they did. These well-conducted, 
rigorous research studies with results that have been reviewed 
by peer scientists prior to publication in leading medical journals 
were conducted in a wide range of settings in Africa, including 
better-resourced settings such as Botswana and South Africa. For 
example, in a clinical trial in urban Botswana where women were 
randomised either to formula from birth or breastfeeding for 6 
months, a doubled risk of death was observed among uninfected 
infants born to HIV-infected mothers.5 In this study, participants 
were carefully screened to ensure all had access to clean water and 
adequate sanitation, formula was provided free, counselling and 
support around formula feeding was extensive, and there was a 
well-functioning health service safety net. In another example in 
a well-resourced area in rural Uganda, with a sophisticated health 
service, women were counselled about infant feeding options 
following AFASS (affordable, feasible, acceptable, sustainable and 
safe – the acronym summarising the criteria that were proposed 
at that time as the requirement for formula feeding to be the 
better choice) and a 6-times greater risk of infant mortality was 
observed among women who selected formula feeding because 
they felt it was ‘AFASS’ for themselves.6 There are several other 
studies, including numerous studies from South Africa.7-14 The 
consistency of the findings across diverse settings, across different 
study designs and with established biological processes makes 
it highly unlikely that the dangers of formula can be explained 
away as part of the vagaries of clinical research methodology. The 
findings of these studies, in conjunction with research findings 
demonstrating the efficacy of ARVs to significantly reduce the risk 
of HIV infection through breastfeeding, iteratively led the WHO 
to revise its recommendations from a position of recommending 
formula feeds as the default feeding practice for HIV-infected 
mothers, to recommending breastfeeding with ARVs.
Saloojee et al. dismiss this large body of research with the claim 
that it comes from settings with much higher rates of infant 
morbidity and mortality than those observed in South Africa (or 
those parts of South Africa with more resources). This is not true 
i.r.o. Botswana and other countries, such as Zambia and Malawi, 
that are more economically disadvantaged, and manifests a 
confusion between an absolute and a relative risk. An absolute 
risk quantifies the likelihood that an event will occur in a group; 
e.g. the risk of dying is 40 per 1 000. A relative risk compares two 
groups: group A has an absolute risk of 40 per 1 000 and group 
B has an absolute risk of 80 per 1 000, therefore the relative risk 
of group B v. group A is double. Even in countries with very low 
absolute rates of infant mortality, such as the USA, UK and the 
Netherlands, formula increases mortality; i.e. the relative risk is 
elevated.15-17 But in countries with higher absolute infant mortality 
rates, the same relative risks translate into a larger absolute 
number of infant deaths. Moreover, synergy occurs: in populations 
with high absolute mortality rates, relative risks of death owing 
to formula are also higher; for example, water contamination, 
lack of access to adequate sanitation and poor health service 
infrastructure exacerbate the dangers of formula. But economic 
disadvantage does not create the biological disadvantage of 
formula. There is no threshold below which formula no longer 
causes harm. Breastfeeding saves lives in all countries – South 
Africa is no exception.
Saloojee et al. misquote three studies18-20 as evidence that 
replacement feeding can be safely accomplished. These studies do 
report equivalent or better outcomes with replacement feeding; 
however, the outcome reported is HIV-free survival, and at a time 
when ARVs were not available to prevent HIV infection through 
breastfeeding. HIV-free survival is a composite endpoint defined 
by the absence of either infant HIV infection or infant death. As 
a public health indicator, it is useful as it reminds us that there is 
little point in saving infants from HIV if they are only going to die 
of other causes. However, consideration of only HIV-free survival 
does not provide proof of safety of formula feeds. Equivalent 
HIV-free survival means that the number of HIV infections 
averted has been cancelled by the number of additional 
uninfected deaths caused.
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These stark statistics do not resolve the question of whether 
breastfeeding alone or formula feeding is the better feeding practice 
for HIV-exposed infants. New data from research studies undertaken 
in over 6 countries, including South Africa, completely transform 
the context in which the dilemma of infant feeding by HIV-infected 
mothers should be considered. ARV intervention can be used 
during breastfeeding to reduce the risk of transmission.21-28 None 
of the studies referred to above used ARVs during breastfeeding; 
the Kenyan study was done before even short-course perinatal 
interventions became available. These studies are uninformative 
for the current era when ARVs are available to prevent transmission 
through breastfeeding. Saloojee and colleagues remain locked into 
an evidence base and paradigm that does not recognise the potency 
of ARVs and the opportunity they present to improve the health and 
survival of HIV-exposed infants.
SOUTH AFRICA HAS PERSISTING INEQUITIES IN HEALTH 
AND WEALTH
As an argument in support of free formula, Saloojee et al. remind 
us that South Africa is not a single homogenous country. This is 
absolutely true. South Africa is a country is with gross disparities in 
wealth, health and living conditions. This is not an argument for the 
government to support formula for the better-off. To the contrary, 
new government policies can serve to reduce inequities and provide 
highly effective interventions to everyone and not just a number of 
favoured groups; the new national policies proactively consider the 
needs of the poor first – as public health policies should.
In Saloojee et al.’s view, the government should provide free 
formula for women in the wealthier provinces, such as Gauteng 
and Western Cape, where women are sufficiently well-off to meet 
AFASS criteria but not so much as to purchase formula themselves. 
Yet this contradicts the first ‘A’ of AFASS, which is ‘affordable’ – a 
point which they seem to ignore. But it’s not actually the A which 
is most relevant – it’s the S for safety. Back to the first point: 
formula feeding is dangerous.
STUDY THE NUMBERS – THEY MATTER
It is therefore, reasonable to ask why HIV-positive women in the 
United States are required to formula feed. It is imperative to pay 
close attention to the actual absolute and relative risks in the 
South African context. Saloojee et al. in their protest to the Mail & 
Guardian claim that, since infant mortality may be as low as 25 per 
1 000 in some better-off parts of South Africa, this figure is below 
the ‘accepted’ threshold where formula feeding can be considered 
‘safe’. The basis for this claim is mathematical modelling, conducted 
by several different groups (including myself )29 in the 1990s, 
calculating the competing risks of HIV transmission associated with 
breastfeeding v. the increased risk of uninfected child deaths owing 
to abstention from breastfeeding. A ‘safe’ threshold is the point at 
which the number of HIV infections averted by formula is exactly 
equivalent to the number of deaths caused by formula feeding – 
hardly a basis for a resounding endorsement of formula. Nevertheless, 
the primary limitation of the models used by Saloojee et al. is that 
they ignore the new opportunities provided by ARV strategies. ARVs, 
when used throughout lactation, significantly reduce the risk of 
HIV transmission via lactation.30 If one applies the new rates of HIV 
transmission observed when ARVs are given, the infant mortality 
rate has to fall to below 10 per 1 000 before the increased number of 
deaths caused by formula feeding is counterbalanced by the number 
of HIV infections averted. Only when the infant mortality rate is <8 
per 1 000 live births, is formula able to save one child per 1 000. If 
transmission rates are lower than assumed in the model, and are as 
low as observed in clinical trials, such as the trial in Botswana,22 or 
risks associated with formula feeding are higher than observed in 
clinical trial settings,5 as is likely to occur in practice, infant mortality 
rates need to be even lower before formula can be considered a 
desirable option (Fig. 1). The infant mortality rate is nowhere near 
this level in any of the populations affected by HIV in South Africa, 
even in the wealthier provinces. New government policies take into 
account the newest up-to-date data, in contrast to the complaints 
made by Salojee et al. that rely on out-of-date data and arguments 
that exclude the availability of ARVs.
ANTIRETROVIRAL DRUGS PROVIDE A SOLUTION TO THE 
INFANT FEEDING DILEMMA
Many commentators are blithely optimistic about the safety of 
formula, yet this optimism does not extend to ARV strategies. 
Regarding the benefits of ARV strategies to prevent mother-to-
child HIV transmission, they state these strategies are unproven, 
based on inference, and with many ‘unanswered questions’. This is 
surprising, since these authors have been at the forefront of testing 
ARV drug strategies and have published data showing the efficacy 
and safety of drug interventions and have been highly active in 
supporting their successful roll-out in Gauteng and elsewhere in 
South Africa.31,32 South African researchers have a stellar record in 
implementing ARV-based programmes including demonstrating 
the capacity of the routine health services to provide effective ARV 
strategies for pregnant HIV-positive women.33-35 This is not to say 
that ARV programmes are easy to implement and that they may 
fall short. But pessimism, and claiming that failure to implement 
perfect programmes will have ‘drastic consequences’, damages 
mobilisation of resources and the will to implement these 
programmes. ARV drug strategies are highly effective in reducing 
mother-to-child HIV transmission through all routes, including 
breastfeeding, and save women’s lives. Programmes to implement 
these strategies should be supported, not disparaged.
My major concern about this pessimism is that it implies 
that formula is a better option than ARV drugs. This is deeply 
Fig. 1. Breastfeeding with ARVs results in better HIV-free survival when 
infant mortality rates exceed 10 per 1 000. The graph shows excess adverse 
outcomes (uninfected infant deaths or HIV infections) per 1 000 as a result 
of formula-feeding, compared with breastfeeding among HIV-infected 
women in populations of varying infant mortality rates. The models allow 
a transmission rate (TR) of 2% assuming ARVs are given and a best-case 
scenario of 1.3%, consistent with the Botswana clinical trial22 of which 
0.3% were due to breastfeeding acquired infections. The model assumes 
a relative risk (RR) of 2 which is consistent with best-case scenario of 
clinical trial-supported formula feeding in a better-off environment 5 
and considers RR=3 more likely to represent the programmatic setting. 
All values >0 indicate that breastfeeding results in better net outcomes; 
values <0 indicate that formula-feeding results in better net outcomes.
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disturbing because formula does nothing to prevent mother-to-
child transmission that can occur during pregnancy and delivery. 
Formula does nothing to improve maternal health. Even if formula 
is provided, ARV treatment and prophylactic regimens remain 
vital. Based on current criteria, a large proportion of pregnant HIV-
positive women meet criteria for ARV treatment. They need this 
treatment as a matter of urgency for their own survival and well-
being, and this treatment needs to be lifelong. To my mind, it is 
problematic to argue against ARV therapy because formula is more 
cost-effective in preventing HIV transmission in a select group of 
mothers and children. Women who meet criteria for treatment are 
responsible for a large proportion of the infant infections (>80% of 
postnatal infections).36 Therefore, purely implementing standard 
adult guidelines for provision of ARV therapy for pregnant women 
who require it based on their own health status would address 
the majority of postnatal HIV infections and would also reduce 
maternal deaths. Choices of infant nevirapine prophylaxis (option 
A), or therapeutic regimens that are stopped after the cessation of 
breastfeeding (option B), are available to address the remaining 
small proportion, but apply only to those asymptomatic women 
with high CD4 counts. The focus of public health interventions 
needs to be on reaching the women who need treatment for their 
own health and who are also most likely to transmit.
HIV IS NOT THE ONLY DISEASE FROM WHICH CHILDREN 
NEED TO BE PROTECTED
Saloojee et al. argue that ‘[a]n HIV-free generation can never 
be achieved while breastfeeding continues.’ This is true. But 
this statement could be more properly rephrased ‘An HIV-free 
generation can never be achieved while pregnancy continues.’ 
Current ARV drug regimens do not result in zero transmission even 
in formula-fed populations. When ARV drug regimens were started 
early in pregnancy and continued through breastfeeding in a study 
in Botswana, the overall transmission rate, including transmissions 
that occurred during breastfeeding, was 1.1%. More than 75% of 
the HIV infections were detected at birth and had occurred before 
delivery. Transmission during 6 months of breastfeeding when 
ARV drugs were given was 0.28%.22 Eliminating breastfeeding will 
not eliminate HIV transmission. Eliminating breastfeeding will, 
however, increase infant mortality.
BREASTFEEDING RIGHTS AND WRONGS
It was not clear from the arguments presented by Saloojee et al. 
what the basis was for the charge that withdrawal of free formula 
was unconstitutional. It may be the denial of the ‘opportunity to 
have an HIV-uninfected child’ that will result if women are denied 
access to formula despite meeting AFASS criteria. This rhetoric is 
seductive but not based on fact. Formula will not guarantee that 
an HIV-positive woman has an uninfected child. Without ARV 
drugs, transmission will occur during pregnancy or delivery in 
about a quarter of women. With adequate ARV drugs given during 
pregnancy and then stopped, transmission rates would be around 
2%, assuming complete abstinence from breastfeeding. A woman 
may have a ‘right’ (in the broadest sense of the word) to purchase 
harmful commodities if she so chooses – just as she has a ‘right’ to 
smoke during pregnancy if she so chooses. However, to claim that a 
woman has a constitutional right to be given harmful products by 
the health services simply because they prevent HIV transmission, 
is wrong. Moreover, Saloojee et al. fail to mention children’s rights, 
also protected in the South African constitution and detailed in 
the Convention of the Rights of Children. This is more than just 
avoidance of HIV infection.
Health policies should not be decided upon by popularity contest. 
National health authorities should solicit opinions on policies so 
that they are sensitive to communities’ needs, but the policies 
themselves need to be based on biological and public health 
principles and evidence. Involvement of the HIV-infected and 
-affected community is central. Children, who can be both infected 
and affected by HIV, need special lobby groups to attend to their 
interests. The majority of HIV-positive women care about HIV 
transmission to their infants and their overall health, well-being 
and survival. The answer of the health service to an HIV-positive 
woman’s question about how best to feed her infant should not be 
a blunt ‘your choice’.
A WAY FORWARD
It is time to put aside polarising debates and conflicts, and come 
together to address the fundamental public health challenges 
facing South Africa. Programmes to support breastfeeding need 
to be strengthened. This includes addressing the education 
of healthcare workers so that correct information is conveyed 
to parents, as well as activism to challenge labour and other 
policies that deny the rights of breastfeeding women. HIV can 
be treated with ARVs, and those receiving ARVs have a very low 
risk of transmitting HIV to their child or sexual partners. We 
should synergise to ensure that all people living with HIV have 
access to effective care and treatment. Strengthening these ARV 
programmes can greatly improve maternal and child health in 
South Africa.
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